Rectal and Liver Metachronous Cancers and Sorafenib-Induced Thyroid Dysfunction

Ancuta Augusta Gheorghisan Galateanu1,2, Mara Carsote2,3*, Dan Peretianu4, Cristina Iosif4, Dana Terzea5,6 and Catalina Poiana2,3

1Department of Cellular and Molecular Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
2C.I.Pharon National Institute of Endocrinology, Bucharest, Romania
3Department of Endocrinology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
4SCM Povernei Medical Centre, Bucharest, Romania
5OncoTeam Monza Hospital, Bucharest, Romania
6“Sfanta Maria” Hospital, Bucharest, Romania

Abstract

Background: The tyrosine kinase inhibitor, a new treatment option in hepatic carcinoma, may associate thyroid dysfunction like spontaneously remitting thyrotoxicosis followed by hypothyroidism.

Case report: A 66-year Caucasian female was first diagnosed and operated for a moderately differentiated rectal adenocarcinoma of 5 centimeters. Immunohistochemistry showed positive VEGF receptor 2 (Flt-1, KDR), VEGF receptor 1(Flk-1), and a Ki67 of 30%. 4 years later a hepatic adenocarcinoma (clear celle variant) was diagnosed. After surgery, daily 400 mg of sorafenib was introduced. Three months later mild symptomatic thyrotoxicosis was seen: palpitations, fatigue, and mild bilateral pedal clonus. Thyroid-stimulating hormone (TSH) was suppressed (0.044 µIU/mL, normal levels between 0.4 and 4.5 µIU/mL), and free levothyroxine (fT4) elevated. The TSH receptor antibody, the antithyreoglobulin and antithyreoperoxidase antibodies were negative. Thyroid ultrasound pointed hypoechogenic, inhomogeneous aspects. She received beta-blocker and within two months thyrotoxicosis remitted but TSH progressively increased suggesting hypothyroidism with level less 5 µIU/mL so no replacement levothyroxine therapy was added yet.

Discussions: The exact mechanism of the tyrosine kinase inhibitors-related thyroid malfunction is not fully understood. Non-autoimmune destructive thyroiditis of unknown trigger causes thyrotoxicosis and later hypothyroidism as seen in our case. The clinical features vary from one person to another. The hormone replacement is rarely necessary. The baseline cancer seems irrelevant for thyroid toxicity. In our usual case the patient had a history of two metachronous cancers. The thyroid follow up is essential during each patient therapy yet a specific pattern of follow-up is not precisely designed.

Conclusion: The tyrosine kinase inhibitor-induced thyroid dysfunction includes both thyrotoxicosis and hypothyroidism. We emphasize the idea of periodic endocrine evaluation in oncoplastic patient treated with this class of drugs.

Keywords: Sorafenib; Tyrosine kinase inhibitor; Thyrotoxicosis; Thyrotoxicosis; Hypothyroidism

Introduction

The drugs involved in destructive thyroiditis exponetially extended during the last decades. The tyrosine kinase inhibitors especially those with small-molecule as sorafenib, sunitinib or axitinib represent an oral treatment options in hepatic or advanced renal cell carcinoma, breast cancer, gastrointestinal stromal tumors, metastatic iodine-refractory thyroid malignancy, or (potential) ovarian cancer [1,2]. This class has less toxicity than traditional systemic cytotoxic drugs although it is potentially correlated to thyroid dysfunction thus a multidisciplinary approach is essential in managing the patient. The initial observations that thyroid malfunction is a relatively rare reaction have been replaced to the concept that actually there is a frequent thyroid disturbance [3-5]. The thyroid involvement includes spontaneously remitting thyrotoxicosis and hypothyroidism [3-5]. The severity of the thyrotoxicosis varies considerably from one patient to another up to thyroid storm especially after sorafenib [3]. One in four cases with sorafenib-induced hypothyroidism had before (within months) a transient thyrotoxicosis associated with a limited number of symptoms or even completely asymptomatic [4,5].

The prevalence of the thyroid diseases in tyrosine kinase inhibitors users varies. For example 36% of a series with 42 gastrointestinal stromal tumors had hypothyroidism within a median of 37 weeks after sunitinib [6]. Up to 85% of a series with patients under sunitinib for renal cells cancer developed hypothyroidism [7]. 8 out of 25 patients with advanced renal cancer developed hypothyroidism and 6 of them had transient thyrotoxicosis [8]. In a series of 33 patients with metastatic renal cells cancer, 6 of 6 (100%) patients treated with axitinib, 9 of 15 (60%) patients treated with sunitinib, and 6 of 12 (50%) patients treated with sorafenib had thyroid dysfunction. [9]. It seems that sunitinib is more frequent correlated with hypothyroidism while sorafenib causes thyroid malfunction in two thirds of the patients, less than a third of them will eventually need thyroid replacement [4]. Pazopanib, another tyrosine kinase inhibitor, has the lowest rate of thyroid toxicity (one tenth of patients) [10].

We report an unusual case with transient mild thyrotoxicosis and later hypothyroidism while using sunitinib in liver cancer, after a previous rectal neoplasia.

*Corresponding author: Mara Carsote, C.I.Pharon National Institute of Endocrinology, Bucharest, Romania, Aviatorilor Ave 34-36, postal cod 011863, Romania, Tel: +40744851934; Fax +40213170607; E-mail: carsote_m@hotmail.com

Received May 16, 2015; Accepted May 26, 2015; Published May 27, 2015

Citation: Gheorghisan Galateanu AA, Carsote M, Peretianu D, Iosif C, Terzea D, et al. (2015) Rectal and Liver Metachronous Cancers and Sorafenib-Induced Thyroid Dysfunction. J Clin Case Rep 5: 530. doi: 10.4172/2165-7920.1000530

Copyright: © 2015 Gheorghisan Galateanu AA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Case Report

A 66-year Caucasian female coming from non-endemic zone has an irrelevant personal and family history of thyroid disease. She was first diagnosed with a rectal tumor of 5 centimeters (cm) that was laparoscopically removed 4 years ago. Pathological report indicated moderately differentiated adenocarcinoma with no lymph nodes invasion (Figure 1a). The immunohistochemistry showed negative reaction for VEGFR, EGFR, CERB2, COX2, zonal positive reaction for VEGF receptor 1 (Flk-1, KDR), VEGF receptor 1 (Flt-1) (Figure 1b), and a Ki67 of 30% (Figure 1c). While she was followed-up a hepatic tumor of 10 cm was revealed by ultrasound and then confirmed by computed tomography at the inferior level of right liver lobe. Persistent high levels of hepatic enzymes were registered (up to a level three times higher than normal). A partial liver resection of the fifth hepatic segment was performed (together with colecistectomy). The histological exam showed a second neoplasia (not a hepatic metastasis) represented by a hepatic adenocarcinoma (clear cells variant) (Figure 1d). The immunohistochemistry revealed VIM negative in tumor cells, Ck7 negative in tumor cells and positive in biliary ducts, negative reaction for EMA, CD10, CROMO, Ck19, and diffuse positive reaction for OCH1E5 in tumor cells. Therapy with sorafenib was started. At baseline she had normal thyroid function and 3 months later she developed clinically mild thyrotoxicosis (while she was on a daily dose of 400 miligrams sorafenib). She accused palpitations, fatigue, associating a mild bilateral pedal clonus, some proximal myopathy, and tachycardia (up to 105 beats per minute). The thyroid hormones revealed a very low level of thyroid-stimulating hormone (TSH) of 0.044 µIU/mL (normal levels are between 0.4 and 4.5 µIU/mL), and elevated free thyroxine (fT4) of 26.8 pmol/L (normal levels are between 12 and 22 pmol/L). The TSH progressively increased up to hypothyroidism ranges but the levels remained less than a level of 5 µIU/mL so no levothyroxine therapy was added yet.

![Figure 1: (a) Moderately differentiated rectal adenocarcinoma, hematoxilin-eosin stain 40× (b) moderately differentiated rectal adenocarcinoma. The areas with positive VEGF receptor 1(FLt-1) 100× (c) moderately differentiated rectal adenocarcinoma. Areas with positive Ki67 100× (d) Hepatocellular carcinoma clear cell variant hematoxilin-eosin stain 20×.](Image)

Discussions

The exact mechanism of the tyrosine kinase inhibitors-related thyroid toxicity is not fully understood. Apparently the hypothyroidism is secondary to a destructive thyroiditis which causes first a thyrotoxicosis episode [11,12]. The thyroiditis is pointed in our patient by specific thyroiditis-like ultrasound pattern. One of the hyperthyroidism triggers is the iodine exposure but some data report that sunitinib actually blocks thyroid iodine uptake that is why the iodine induced thyrotoxicosis is less possible [11,12]. Two reports from 2011 in patients with hepatocellular carcinoma treated with sorafenib confirmed that thyroiditis is the major part of sorafenib-induced hypothyroidism [12]. Other mechanism is partly explained by main drug targets: raf-ras pathway, VEGF, FMS-like tyrosine kinase 3 (FLT3) [13]. Another potential path involved in sorafenib-related tumor shrinkage is Jak2-Stat3-Mcl1 axis [13]. Extremely high values of serum TSH are registered in some patients treated with tyrosine kinase inhibitors regardless a previously episode of thyrotoxicosis that is recently considered as a pattern of inappropriate elevation of TSH syndrome [14]. But in most of the cases the TSH goes high normal or slightly elevated as we registered. Another hypothyroidism related mechanisms is the fact that tyrosine kinase inhibitors act as an inhibitor of angiogenesis, and vascular endothelial growth factor (VEGF), having a dual effect on the tumor cells and vasculature with thyroid atrophy [15]. The thyroid anomalies are more frequent seen in relationship to sunitinib probably because of the effect not only on VEGF receptor 2 (Flk1, KDR) but also on VEGF receptor 1 (Flt-1), and PDGFR (platelet-derived growth factor receptor) [15]. Other mechanism is abnormal iodine uptake at the level of thyroid and consecutive inhibition of thyroid peroxidase [11,16]. It is generally accepted that no autoimmune mechanism is involved in thyroid dysfunction thus the thyroid related antibodies are negative as in this case where all three thyroid antibodies [17].

The clinical management in oncologic patients includes a multidisciplinary approach: oncology, surgery, pathology, and endocrinology. In patients intend to be treated with tyrosine kinase inhibitors a baseline endocrine (thyroid) evaluation is necessary and then close monitoring every four to eight weeks. A specific pattern of follow-up is not yet precisely designed [15-17]. The thyroid toxicity is registered in a general panel of adverse reactions since the tyrosine
kinase inhibitors as sorafenib (a multikinase inhibitor) or sunitinib (an inhibitor of both VEGFR and PDGFR) have proven their oncologic efficacy and had their approve by Food and Drug Administration since 2005/2006 [18]. The frequent dose interruptions are seen including from the first month of therapy [18]. The discontinuation of the drug in case of severe negative effects does not exclude the possibility of drug re-administration [19]. Severe thyrototoxicosis may represent a life threat situation with rapid medical intervention and hypothyroidism needs long term thyroid hormones replacement at high TSH values while the patient is still under tyrosine kinase inhibitor [18-20]. Different data suggest that thyroid replacement therapy does not influence the surviva [20]. Regarding our case the thyroid hormones excess was clinically evident and the hypothyroidism remained asymptomatic. If the targeted anti-cancer therapy is started in a previously known patient with hypothyroidism the levothyroxine requirement increases [21]. In a cohort study of 1214 patients under sorafenib, and 1295 patients under sunitinib, 6.3% respective 13.7% associated hypothyroidism (incidence rate of 12.1 respective 24.2 per 100 person-years) [22]. The thyroid toxicity does not seem to be influenced by the type of cancer [22]. In our case two major observations are necessary: the diagnosis of thyrototoxicosis was later than seen in most of the studies, and the patient has been diagnosed during her life with two cancers. It is difficult to suggest that metachronous cancer increase the risk of sorafenib related thyroid malfunction.

As the prognosis factors of thyroid dysfunction are still a matter of date, a continuous follow-up of the patients currently treated with tyrosine kinase inhibitors is necessary. A retrospective chart review from 2005 to 2011 pointed that drug induced hypothyroidism is correlated to a longer progression-free survival, and it may be considered as a surrogate in evaluation of disease control under therapy [23]. Similar data are displayed by a prospective study on patients with metastatic renal cancer treated with sorafenib or sunitinib between 2006 and 2009. 31.8% of patients developed hypothyroidism, and this particular group had a longer progression-free survival: 16 ± 0.8 months versus 6 ± 0.8 months, p value=0.032 [20]. 76% of patients with hypothyroidism increased TSH after first months of therapy [20]. A meta-analysis from 2014 (including 12 clinical trials) showed the hypothyroidism relative risk of 3.59 (96% CI=2.4-5.38, p ≤ 0.0001) and the type of tumor did not influence this risk [24].

Recent data pointed that thyroid anomalies may be a class effect, and the general (as well as thyroid) toxicity is not connected to a specific pattern of pharmacokinetics regarding age, sex, ethnicity or weight (that is why the dose are not adjusted based on these factors) [25]. The controversies related to the timing and adequate dose in thyroid hormone replacement are still a matter of debate [26]. Many authors consider that unless clinical sever symptoms the hypothyroidism should not be treated [27] For example apart from low thyroid hormone levels levothyroxine therapy should be initiated in case TSH greater than 10 mUI/l [28]. The thyrototoxicosis management varies from no therapy to corticosteroids and beta-blockers [28]. Thionamides are sometimes empirically administered but there is no real benefit in destructive thyroiditis [28]. In case of hepatic cancer with high serum liver enzymes this biochemistry aspect may also be caused by the thyroid malfunction. Based on all these particular and general data that we presented we conclude the practical endocrine aspects in patients diagnosed with different types of cancer who need to be treated with tyrosine kinase inhibitors. At baseline TSH and freeT4 control is necessary and then periodically repeated (like every 1-2 months). If thyroid dysfunction is found the investigations should also include thyroid ultrasound and antibodies. If thyrototoxicosis is registered the symptomatic therapy as beta-blockers is advised and the thyroid function measured every month up to its normalization. If TSH is increased the levothyroxine replacement therapy is better to be postpone unless TSH is very high while checking TSH level every 4 to 8 weeks. In most of cases the anticancer drug should be continued despite thyroid dysfunction.

Conclusion

The tyrosine kinase inhibitor-induced thyroid toxicity is presented as both thyrotoxicosis and hypothyroidism. The periodic thyroid check up is necessary. The clinical aspects vary and the underlying cancer seems to be irrelevant in this adverse reaction.

References

1. Faris JE, Moore AF, Daniels GH (2007) Sunitinib (sutrfei)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid 17: 1147-1149.
2. Smoel E, Taucher V, Petru E, Haybaec K (2014) Targeted treatment of ovarian cancer—the multiple - kinase - inhibitor sorafernib as a potential option. Anticancer Res 34: 1519-1530.
3. Haraldsdottir S, Li Q, Villalona-Calero MA, Olencki TE, Kendra K, et al. (2013) Case of sorafernib-induced thyroid storm. J Clin Oncol 31: e262-264.
4. Miyake H, Kuralhashi T, Yamanaka K, Kondo Y, Muramaki M, et al. (2010) Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafernib: a prospective evaluation. Urol Oncol 28: 515-519.
5. Sakurai K, Fukazawa H, Aihara Z, Yoshida K (2010) Sorafernib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. Tokohu J Exp Med 222: 39-44.
6. Desai J, Yassa L, Marquese E, George S, Frates MC, et al. (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145: 860-864.
7. Rini BI, Tamsaski I, Shaheed P, Salas R, Garcia J, et al. (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sorafernib. J Natl Cancer Inst 99: 81-83.
8. Grossmann M, Prenaratne E, Desai J, Davis ID (2008) Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 69: 669-672.
9. Daimon M, Kato T, Kaino W, Takase K, Karasawa S, et al. (2012) Thyroid dysfunction in patients treated with thyrosine kinase inhibitors, sunitinib, sorafernib and axitinib, for metastatic renal cell carcinoma. Jpn J Clin Oncol 42: 742-747.
10. Sterenberg CN, Davis ID, Mardiak J, Szczyliz C, Lee E, et al. (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061-1068.
11. Mannavalvo D, Coco P, Vannucchi G, Bertuelli R, Carleitto M, et al. (2007) A novel tyrosine-kinase-selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92: 3531-3534.
12. van Doolom L, Eskenfs FA, Visser TJ, van de Lugt A, Mathijssen RH, et al. (2011) Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid 21: 197-202.
13. Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldberg D, et al. (2013) Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLOS One 8: e75414.
14. Ohka K, Takayama T, Matsunaga H, Matsushita A, Sasaki S, et al. (2013) Inapproporat elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid 23: 443-444.
15. Makita N, Iiri T (2013) Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid 23: 151-159.
16. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, et al. (2007) Sunitinib-induced thyroiditis in two patients with hepatocellular carcinoma. Ann Intern Med 145: 660-664.
17. Daimon M, Kato T, Kaino W, Takase K, Karasawa S, et al. (2012) Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Jpn J Clin Oncol 42: 742-747.
18. La Vine DB, Coleman TA, Davis CH, Carbomelle CE, Davis WB (2010) Frequent
dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. Am J Clin Oncol 33: 217-220.

19. Johannsen M, Flörcken A, Bex A, Rojas J, Cosentino M, et al. (2009) Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 55: 1430-1438.

20. Riesenbeck LM, Bierer S, Hoffmeister I, Köpke T, Papavassilis P, et al. (2011) Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol 29: 807-813.

21. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G (2009) Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 6: 219-228.

22. Feldt S, Schüessler K, Quinzler R, Franzmann A, Czeche S, et al. (2012) Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. Eur J Cancer 48: 974-981.

23. Clemons J, Gao D, Naam M, Breaker K, Garfield D, et al. (2012) Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin Genitourin Cancer 10: 225-231.

24. Abdel-Rahman O, Fouad M (2014) Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. Expert Rev Anticancer Ther 14: 1063-1073.

25. Di Gioia P, Kanesfet D, Lindauer A, Scheffler M, Doroshyenko O, et al. (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 50: 551-603.

26. Fallahi P, Ferrari SM, Vita R, Di Domenicantonio A, Corrado A, et al. (2014) Thyroid dysfunctions induced by tyrosine kinase inhibitors. Expert Opin Drug Saf 13: 723-733.

27. Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, et al. (2008) Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19: 265-268.

28. Bianchi L, Ross L, Tomao F, Papa A, Zoratto F, et al. (2013) Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma. Endocr Relat Cancer 20: R233-245.

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:
- User friendly/feasible website-translation of your paper to 50 world’s leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:
- 400 Open Access Journals
- 30,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: http://www.omicsonline.org/submission